Related Experiment Video
Updated: Oct 3, 2025

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
Published on: May 17, 2015
mTOR signaling cascade: novel clinical implications in HLA and non-HLA antibody-mediated vasculopathies?
Kevin Louis1, Alexandre Loupy2, Carmen Lefaucheur1
1Paris Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, Unite de Mixte Recherche S970, Université de Paris, Paris, France; Kidney Transplant Department, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Abstract:
Antibodies targeting endothelial antigens represent major threats to the integrity of endothelial vasculature, contributing to development of organ transplant rejection and vasculopathies. In this issue, Catar et al. present the mechanisms by which non-human leukocyte antigen angiotensin II type 1 receptor and endothelin-1 type A receptor antibodies mediate impairment of endothelial repair via β2-arrestin link to the mammalian target of rapamycin pathway. This commentary discusses the mechanisms of human leukocyte antigen and non-human leukocyte antigen antibody-endothelium interactions, and the clinical implications and challenges of the use of mammalian target of rapamycin signaling activation as biomarker and therapeutic target in vasculopathies.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Intracellular Signaling Affects Focal Adhesions
Some...
Non-Canonical Wnt Signaling Pathways

